-
Stocks drop, oil climbs after fresh Trump warning to Iran
-
Twins wow Cannes with 'mesmeric' tale of Nigeria's rich
-
New Ebola outbreak in DR Congo: What we know
-
Iran Nobel winner discharged from hospital: supporters
-
Spanish court orders 55 mn euro tax refund to Shakira
-
Ryanair flags Iran war uncertainty as annual profit jumps
-
Hearts have bright future despite Scottish title pain: McInnes
-
Fernandes 'proud' to match Premier League assists record
-
Germany set to miss 2030 climate goal: experts
-
G7 finance chiefs meet to seek common stance on unstable ground
-
Hantavirus-hit cruise ship docks in Rotterdam at voyage end
-
Philippines swears in senators for VP Duterte's impeachment trial
-
Iran's World Cup football team leaves for Turkey: media
-
Hantavirus-hit cruise ship steams towards Rotterdam at voyage end
-
Japan arrests Americans over stunt at baby monkey Punch's zoo
-
Trump says 'clock ticking' for Iran as peace negotiations stall
-
Hong Kong court hears closing arguments in Tiananmen activists' trial
-
World Cup duo Ghana, Cape Verde not among AFCON top seeds
-
African players in Europe: Daring Semenyo wins final for City
-
Kenya's new poaching problem: smuggling Giant Harvester Ants
-
WHO kicks off annual assembly amid hantavirus, Ebola crises
-
S. Korean blockbuster 'Hope' underscores growing film ambition
-
Train driver charged after deadly Bangkok bus collision
-
Angry Chinese table tennis fans demand apology for flag gaffe
-
India's lifeline ferry across strategic archipelago
-
Encroaching world threatens India's last 'uncontacted' tribe
-
India's strategic $9 bn megaport plan for pristine island
-
In Tierra del Fuego, a hunt for the rodent carrier of hantavirus
-
Mitchell leads Cavs past top-seeded Detroit into NBA East finals
-
China's April consumption, factory output growth slowest in years
-
Asian stocks sink, oil rises on US-Iran deadlock
-
Cleveland Cavaliers eliminate top-seeded Detroit from NBA playoffs
-
Who could be the 2026 World Cup's breakout star?
-
Humble PGA champ Rai celebrates English, Indian, Kenyan heritage
-
Hantavirus-hit cruise ship nears end of voyage, to dock in Rotterdam
-
He said, she said, AI said: Wall Street sex scandal rivets and confounds
-
UN General Assembly to take up climate change 'obligations' resolution
-
Four takeaways from Musk vs OpenAI trial
-
Jury to decide fate of Musk's blockbuster suit against OpenAI
-
Frustrated McIlroy drops F-bomb in exchange with PGA heckler
-
Defending champion Palou storms to Indy 500 pole
-
Messi shines as Inter Miami finally win at new stadium
-
Shai Gilgeous-Alexander wins second straight NBA MVP award
-
White House mass prayer event seeks to reclaim US Christian roots
-
International dive group joins Maldives search for missing Italians
-
'Staggering' Iran toll drives up global executions: Amnesty
-
Kingsway Publishes Investor Day Presentation to Company Website
-
Helio Ignites Space Infrastructure IP Race with Patent Filing for Deployable Boom Tech, Positioning as Future Leader in Space-Based Solar Power and Orbital Systems
-
Ryde Appoints Chief Product Officer to Accelerate Platform Innovation and Marketplace Growth
-
XCF Global Highlights Long-Term Growth Drivers for Renewable Fuels as U.S. Biofuel Policy Evolves and SAF Demand Continues to Build
France to 're-shore' production of 50 key medicines: Macron
France will bring home production of around 50 crucial medications for which it currently depends on imports, President Emmanuel Macron said Tuesday, hoping to battle shortages of items like antibiotics and paracetamol.
Of the initial slate of drugs with a "clear dependence on imports from outside the EU", 25 "will have their production re-shored or significantly increased... in the coming weeks," Macron said during a visit to a pharmaceuticals factory in southern France.
The announcement comes after a March survey by pollsters BVA found 37 percent of people had already run into shortages at the pharmacy.
Up to 80 percent of familiar medications like antibiotics and painkillers used in France are produced abroad, especially in China.
Some of the drugs are still made in France, but at volumes that fail to match demand.
Over the winter, Europe faced shortages of key antibiotic amoxicillin and other medications as surging illnesses particularly among children have increased demand for the drugs.
Under Macron's plan, public money to the tune of 160 million euros ($173 million) will go to support eight of the new projects, including for amoxycillin -- produced by British pharma giant GSK in northwestern France -- as well as anaesthetics, painkillers and cancer drugs.
Companies would be able to apply for a share of a further 50 million euros in funding, Macron said.
The 50 drugs flagged by Macron are among a list of 450 drawn up by the health ministry for which "we must absolutely secure our supply chains, either by completely re-shoring or diversifying (supply) and continuing to innovate," the president said.
Tuesday's pharma announcements mark the first step in a week dedicated to industrial projects, which Macron hopes will move public attention on from the battles over his widely-disliked pension reform.
B.Finley--AMWN